Legend Biotech Announces Submission of Supplemental Application to the U.S. FDA for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)Business Wire • 06/06/23
Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 StudyBusiness Wire • 06/05/23
Legend Biotech Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)Business Wire • 05/25/23
Legend Biotech to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma at ASCO and EHA Annual MeetingsBusiness Wire • 05/16/23
Legend Biotech Corporation Announces Pricing of Registered Direct Offering of $350 Million of American Depositary SharesBusiness Wire • 05/08/23
Legend Bio Hits Profit-Taking Zone After Reportedly Confirming Key Study ResultsInvestors Business Daily • 04/21/23
Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech NamesBenzinga • 04/20/23
Legend Biotech Corporation Sponsored ADR (LEGN) Soars 19.6%: Is Further Upside Left in the Stock?Zacks Investment Research • 04/20/23
Legend Biotech Breaks Out After Leaked Documents Show Big CAR-T BenefitInvestors Business Daily • 04/19/23